A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT04908202
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days
  • Placebo — OTHER
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Key Dates

Start date
Jul 13, 2021
Status verified
Apr 2026
Primary completion
Sep 5, 2024
Completion
Jun 10, 2027

Study Design

Enrollment
670 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib
  • Placebo Comparator: Placebo

Primary Outcome Measure

Percentage of Participants With ACR 20 Response at Week 16 [ Time Frame: Week 16 ]

Locations (33)

FacilityCityStateZIPSite coordinators
Local Institution - 0197GilbertArizona85297-
Local Institution - 0188JonesboroArkansas72401-
Local Institution - 0168FontanaCalifornia92335-
Local Institution - 0199FullertonCalifornia92835-
Local Institution - 0038SacramentoCalifornia95815-
Cohen Medical CentersThousand OaksCalifornia91360-
Local Institution - 0170DenverColorado80230-
Local Institution - 0195ClearwaterFlorida33765-
Local Institution - 0272MargateFlorida33063-
Local Institution - 0082Miami LakesFlorida33014-
Local Institution - 0171GainesvilleGeorgia30501-
Local Institution - 0087BoiseIdaho83702-
Local Institution - 0080ChicagoIllinois60640-
Local Institution - 0177Orland ParkIllinois60467-
Local Institution - 0178SchaumburgIllinois60195-
Local Institution - 0083LexingtonKentucky40504-
Local Institution - 0042HagerstownMaryland21740-
Local Institution - 0198DetroitMichigan48202-
Local Institution - 0201SpringfieldMissouri65807-
Local Institution - 0268KalispellMontana59901-
Local Institution - 0186Voorhees TownshipNew Jersey08043-
University Hospitals Cleveland Medical Center-DermatologyClevelandOhio44106-
Local Institution - 0028Middleburg HeightsOhio44130-
Local Institution - 0179PerrysburgOhio43551-
Local Institution - 0182Oklahoma CityOklahoma73102-
Local Institution - 0185CorvallisOregon97330-
Local Institution - 0175GreenvilleSouth Carolina29601-
Local Institution - 0036JacksonTennessee38305-
Local Institution - 0172AllenTexas75013-
Local Institution - 0189AmarilloTexas79124-
Local Institution - 0032DallasTexas75231-
Local Institution - 0273BothellWashington98021-
Local Institution - 0181BeckleyWest Virginia25801-

Related coverage on Hipa.ai

Find similar trials in Gilbert, AZ

By condition
Psoriatic arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Local Institution - 0197· Gilbert, AZLocal Institution - 0188· Jonesboro, ARLocal Institution - 0168· Fontana, CALocal Institution - 0199· Fullerton, CALocal Institution - 0038· Sacramento, CACohen Medical Centers· Thousand Oaks, CA

Related Studies